US 10,376,518 B2
Methods for the treatment of autoimmune diseases
Shawn Ellis, London (GB); Clare Notley, London (GB); and Michael Ehrenstein, London (GB)
Assigned to UCL BUSINESS PLC, London (GB)
Appl. No. 14/780,104
Filed by UCL Business PLC, London (GB)
PCT Filed Mar. 28, 2014, PCT No. PCT/GB2014/051005
§ 371(c)(1), (2) Date Sep. 25, 2015,
PCT Pub. No. WO2014/155135, PCT Pub. Date Oct. 2, 2014.
Claims priority of application No. 1305714.6 (GB), filed on Mar. 28, 2013.
Prior Publication US 2016/0030439 A1, Feb. 4, 2016
Int. Cl. A61K 39/395 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 31/4155 (2006.01); C07K 16/28 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/4155 (2013.01); A61K 39/3955 (2013.01); A61K 39/39591 (2013.01); A61K 45/06 (2013.01); C07K 16/2809 (2013.01); G01N 33/564 (2013.01); G01N 33/6893 (2013.01); C07K 2317/76 (2013.01); G01N 2333/47 (2013.01); G01N 2333/7051 (2013.01); G01N 2800/102 (2013.01); G01N 2800/105 (2013.01)] 11 Claims
 
1. A method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject:
(i) a first agent which inhibits p38 phosphorylation; and
(ii) a second agent which is an anti-CD3 antibody;
wherein the subject is a non-responder to anti-CD3 therapy alone, showing no significant increase in FOXP3 expression on CD8+ T cells following anti-CD3 stimulation, and wherein the first agent is administered to the subject followed by the second agent or the two agents are administered simultaneously.